Compare NICM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICM | PMN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | Canada |
| Employees | 25 | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 136.2M |
| IPO Year | N/A | 2022 |
| Metric | NICM | PMN |
|---|---|---|
| Price | $5.85 | $12.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 3.0K | ★ 99.3K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.77 | $0.29 |
| 52 Week High | $6.48 | $27.40 |
| Indicator | NICM | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 45.45 |
| Support Level | $5.92 | $9.87 |
| Resistance Level | $6.38 | $14.40 |
| Average True Range (ATR) | 0.16 | 1.37 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 35.34 | 5.22 |
Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.